PROCLAIM-CX-072: Analysis of Patients With Advanced Solid Tumors Receiving Long-Term Treatment With CX-072, a PD-L1 PROBODY Therapeutic, as a Single Agent or in Combination With Ipilimumab

Fiona Thistlethwaite, Aung Naing, Marta Gil-Martin, Patricia LoRusso, Manreet Randhawa, Ferry Albert Louis Maria Eskens, Rachel E. Sanborn, Nataliya Uboha, Daniel Cho, Alexander I. Spira, Igor Bondarenko, Ruth Plummer, Javier Garcia-Corbacho, Ivan Victoria, Javier Lavernia, Ignacio Melero, E.G.E. DeVries, Will Garner, Hendrik-Tobias Arkenau, Johanna Bendell. Oral presentation at the ASCO20 Virtual Scientific Program, May 29-31, 2020.